Abstract
Overexpression of epidermal growth factor (EGF) receptor and HER2 (p185neu) may both contribute to the growth of human cancers. A humanized anti-HER2 monoclonal antibody (mAb) 4D5 and a human-mouse chimeric anti-EGF receptor mAb C225 are currently being investigated in clinical trials for their anti-tumor activities. In the present study, we have examined the effect of concurrent treatment of OVCA 420 human ovarian cancer cells with mAb C225 and mAb 4D5. Exposure of OVCA420 cells to saturating concentrations of C225 (20 nM) for 7 days resulted in 40 – 50% growth inhibition, and exposure to 20 nM mAb 4D5 also resulted in 30 – 40% growth inhibition. The growth inhibition of OVCA420 cells by mAb C225 or 4D5 was associated with an increased G1 cell population; an increased level of a cyclin-dependent kinase (CDK) inhibitor p27Kip1 with increased association of p27Kip1 with CDK2, CDK4 and CDK6; and decreased activities of these CDKs. Combination treatment with concurrent exposure to mAbs C225 and 4D5 resulted in additive anti-proliferative effects on these cells, which was accompanied by enhanced G1 cell distribution, a greater increase in the levels of p27Kip1 and a greater decrease in the activities of CDK kinases. The anti-proliferative effects and related changes in cell cycle regulators induced by mAb 4D5, mAb C225 or the combination of the two mAbs could be reversed by concurrent exposure to exogenous EGF. Our data suggest the potential fruitful cooperation of anti-EGF receptor mAb and anti-HER2 mAb in the treatment of human cancers stimulated by EGF receptor and HER2 signals.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- EGF:
-
epidermal growth factor
- mAb:
-
monoclonal antibody
- CDK:
-
cyclin dependent kinase
References
Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC and Norton L. . 1996 J. Clin. Oncol. 14: 737–744.
Bos M, Mendelsohn J, Bowden C, Pfister D, Cooper MR, Cohen R, Burtness B, D'Andrea G, Waksal H, Norton L and Baselga J. . 1996 Proc. Am. Clin. Oncol. 15: 443.
Chou JL, Fan Z, Koff A and Mendelsohn J. . 1996 Proc. Am. Assoc. Cancer Res. 37: 10.
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Paton V, Shak S, Lieberman G and Slamon D. . 1998 Proc. Am. Clin. Oncol. 17: 97a.
Divgi CR, Welt C, Kris M, Real FX, Yeh SDJ, Gralla R, Merchant B, Schweighart S, Unger M, Larson SM and Mendelsohn J. . 1991 J. Natl. Cancer Inst. 83: 97–104.
Earp HS, Dawson TL, Li X and Yu H. . 1995 Breast Cancer Res. Treat. 35: 115–132.
Fan Z, Lu Y, Wu X, DeBlasio A, Koff A and Mendelsohn J. . 1995 J. Cell. Biol. 131: 235–242.
Fan Z, Lu Y, Wu X and Mendelsohn J. . 1994 J. Biol. Chem. 269: 27595–27602.
Fan Z, Mendelsohn J, Masui H and Kumar R. . 1993 J. Biol. Chem. 268: 21073–21079.
Fan Z, Shang BY, Lu Y, Chou JL and Mendelsohn J. . 1997 Clin. Cancer Res. 3: 1943–1948.
Fan Z and Mendelsohn J. . 1998 Curr. Opin. Onco. 10: 67–73.
Falcey J, Pfister D, Cohen R, Cooper M, Bowden C, Burtness B, Mendelsohn J and Waksal H. . 1997 Proc. Am. Soc. Clin. Oncol. 16: 383a.
Goldman R, Levy RB, Peles E and Yarden Y. . 1990 Biochem. 29: 11024–11028.
Goldstein NI, Prewett M, Zuklys K, Rockwell P and Mendelsohn J. . 1995 Clin. Cancer Res. 1: 1311–1318.
Harris AL, Nicholson S, Stainsbury JR, Farndon JR and Wright C. . 1989 J. Steroid Biochem. 34: 123–131.
Jardines L, Weiss M, Fowble B and Greene M. . 1993 Pathobiology 61: 268–282.
Kawamoto T, Sato JD, Le A, Sato GH and Mendelsohn J. . 1983 Proc. Natl. Acad. Sci. USA 80: 1337–1341.
Laiho M, DeCaprio JA, Ludlow JW, Livingston DM and Massague J. . 1990 Cell 62: 175–185.
Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C and Shepard HM. . 1993 Cancer Immunol. Immunother. 37: 255–263.
Mendelsohn J. . 1990 Sem. Cancer Biol. 1: 339–344.
Morgan DO. . 1995 Nature 374: 131–134.
Pegram M, Lipton A, pietras R, Hayes D, Weber B, Baselga J, tripathy D, Twaddell T, Glaspy J and Slamon D. . 1995 Proc. Am. Soc. Clin. Oncol. 14: 106.
Peles E, Ben-levy R, Tzahar E, Liu N, Wen D and Yarden Y. . 1993 EMBO J. 12: 961–971.
Peng D, Fan Z, Lu Y, DeBlasio T, Scher H and Mendelsohn J. . 1996 Cancer Res. 56: 3666–3669.
Plowman GD, Green JM, Culouscou JM, Carlton GW, Rothwell VM and Buckley S. . 1993 Nature 366: 473–475.
Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher H and Goldstein NI. . 1996 J. Immunother. 19: 419–427.
Qian X, LeVea CM, Freeman JK, Dougall WC and Greene MI. . 1994 Proc. Natl. Acad. Sci. USA 91: 1500–1504.
Reese DM and Slamon DJ. . 1997 Stem Cells 15: 1–8.
Sherr CJ. . 1996 Science 274: 1672–1677.
Scott GK, Dodson JM, Montgomery PA, Johnson RM, Sarup JC, Wong WL, Ullrich A, Shepard HM and Benz CC. . 1991 J. Biol. Chem. 266: 14300–14305.
Shott S. . 1990 Statistics for Health Professionals. Eoyang T. (ed.).. W. B. Saunders Company Press: Philadelphia pp. 151–154.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL. . 1987 Science 235: 177–182.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Press MF. . 1989 Science 244: 707–712.
Slamon D, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Baselga J and Norton L. . 1998 Proc. Am Clin. Oncol. 17: 98a.
Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, Fendly BM, Cerione RA, Vandlen RL and Carraway KLIII. . 1994 J. Biol. Chem. 269: 14661–14665.
Stern DF and Kamps MP. . 1988 EMBO J. 7: 995–1001.
Ullrich A and Schlessinger J. . 1990 Cell 61: 203–212.
Wada T, Qian XL and Greene MI. . 1990 Cell 61: 1339–1347.
Wu X, Rubin M, Fan Z, DeBlasio T, Soos T, Koff A and Mendelsohn J. . 1996 Oncogene 12: 1397–1403.
Acknowledgements
We thank Dr Mark Sliwkowski at Genentech, Inc. for provision of humanized mAb 4D5 (rhumAb HER2, Herceptin) and Dr Harlan Waksal at ImClone systems, Inc. for provision of human-mouse chimeric mAb 225 (C225). We also thank Drs Robert Bast Jr and Gordon Mills at UT MD Anderson Cancer Center for provision of OVCA420 cell line. This study was supported by NIH Grants CA42060 and CA68425 to JM and ZF.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ye, D., Mendelsohn, J. & Fan, Z. Augmentation of a humanized Anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 18, 731–738 (1999). https://doi.org/10.1038/sj.onc.1202319
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202319
Keywords
This article is cited by
-
Molecular recognition of tak-285 and lapatinib by inactive, active, and middle active-inactive HER2
Journal of Molecular Modeling (2021)
-
Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells
Journal of Translational Medicine (2014)
-
Identifying microRNA/mRNA dysregulations in ovarian cancer
BMC Research Notes (2012)
-
Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer
Journal of Cancer Research and Clinical Oncology (2012)
-
Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators
Oncogene (2010)